within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J06B_Immunoglobulins.J06BD03_TixagevimabAndCilgavimab;

model TixagevimabAndCilgavimab
  extends Pharmacolibrary.Drugs.ATC.J.J06BD03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J06BD03</td></tr><td>route:</td><td>intramuscular</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tixagevimab and cilgavimab are two recombinant human monoclonal antibodies targeting the SARS-CoV-2 spike protein, used in combination as pre-exposure prophylaxis and treatment for COVID-19. This combination is approved by regulatory agencies such as the FDA and EMA for certain populations at increased risk of inadequate response to vaccination or exposure.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are based on healthy adult volunteers and immunocompromised patients receiving a single intramuscular administration.</p><h4>References</h4><ol><li><p>Levin, MJ, et al., &amp; Esser, MT (2022). Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. <i>The New England journal of medicine</i> 386(23) 2188–2200. DOI:<a href=\"https://doi.org/10.1056/NEJMoa2116620\">10.1056/NEJMoa2116620</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35443106/\">https://pubmed.ncbi.nlm.nih.gov/35443106</a></p></li><li><p>Forte-Soto, P, et al., &amp; Esser, MT (2023). Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults. <i>The Journal of infectious diseases</i> 227(10) 1153–1163. DOI:<a href=\"https://doi.org/10.1093/infdis/jiad014\">10.1093/infdis/jiad014</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36683419/\">https://pubmed.ncbi.nlm.nih.gov/36683419</a></p></li><li><p>Hobbs, FDR, et al., &amp; Esser, MT (2024). Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial. <i>Infectious diseases and therapy</i> 13(3) 521–533. DOI:<a href=\"https://doi.org/10.1007/s40121-024-00931-4\">10.1007/s40121-024-00931-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38403865/\">https://pubmed.ncbi.nlm.nih.gov/38403865</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end TixagevimabAndCilgavimab;
